SCHEMBL6319291

SCHEMBL6319291

Cc1[nH]c2ccc(C(=O)O)cc2c1Cc1ccc(C=Cc2ccccc2)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.50
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 4/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
TDP1 Q9NUW8 2/20 0.45
PSMD14 O00487 1/20 0.45
RECQL P46063 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
APEX1 P27695 1/20 0.45
PPARG P37231 1/20 0.43
PTGS2 P35354 1/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 6/20 0.40
SRD5A1 P18405 1/20 0.39
SRD5A2 P31213 1/20 0.39
PTPN11 Q06124 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
NPC1 O15118 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320931 1.00 PTPN5 (0.50) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6327242 0.90 PTPN5 (0.45) PTPN5KDM4EALDH1A1HPGDPTGS2
SCHEMBL6327244 0.90 PTPN5 (0.45) PTPN5KDM4EALDH1A1HPGDPTGS2
SCHEMBL6320828 0.85 PTPN5 (0.46) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6321835 0.85 PTPN5 (0.46) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881776 0.85 PTPN5 (0.68) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881779 0.85 PTPN5 (0.68) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881790 0.85 PTPN5 (0.58) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL5881662 0.84 PTPN5 (0.53) PTPN5KDM4EALDH1A1THRBHPGD
SCHEMBL6326527 0.84 PTGS2 (0.44) PTGS2MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
CN-1150167-C Indole derivatives ����ҩƷ��ҵ��ʽ���� 2004-05-19 CN disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
CN-1303371-A Indole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-11 CN disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A PTPN5 108/4885KDM4E 942/4885ALDH1A1 293/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR PTPN5 4723/4885KDM4E 2714/4885ALDH1A1 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.